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Abstract
Background—Approximately 40% of males with the fragile X premutation develop fragile X-
associated tremor/ataxia syndrome after age 50. Although the thalamus and basal ganglia play a
crucial role in movement disorders, their involvement in fragile X premutation carriers has not
been systematically investigated.
Methods—The current study characterized structural abnormalities associated with fragile X
premutation carriers (with and without fragile X-associated tremor/ataxia syndrome) in the
thalamus, caudate nucleus, putamen, and globus pallidus using T1-weighted and diffusion tensor
imaging.
Results—Male premutation carriers with fragile X-associated tremor/ataxia syndrome showed
significant volume atrophy and diffusion-weighted signal loss in all 4 structures compared to the
control group. They also exhibited volume atrophy and diffusion-weighted signal loss in the
thalamus and striatum compared to the premutation carriers without fragile X-associated tremor/
ataxia syndrome. Importantly, many of the measurements exhibited robust correlations with
symptom severity, with volume and DWI measurements displaying negative correlations and
fractional anisotropy measurements displaying positive correlations.
Conclusions—The current study demonstrated involvement of all 4 subcortical gray matter
structures in fragile X-associated tremor/ataxia syndrome, with significant volume atrophy, and
possibly iron deposition indicated by the diffusion-weighted signal loss. The significant
correlation between the subcortical measurements and symptom severity suggests the benefits of
tracking structural changes in the subcortical gray matter in future longitudinal studies for early
detection and disease monitoring.
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Introduction
The fragile X mental retardation 1 (FMR1) gene has a polymorphic CGG repeat in its 5’
untranslated region that normally ranges from 5-44 triplets.1 Premutation alleles with
expansions of the CGG repeat to 55-200 triplets are relatively common in the general
population, representing a prevalence rate of 1:110-250 in females and 1:250-810 in
males.2-4 Among males with the premutation alleles of FMR1 gene, approximately 40%
develop a late-onset neurodegenerative disorder, fragile X-associated tremor/ataxia
syndrome (FXTAS), after 50 years of age.5,6 The principal clinical features associated with
FXTAS are progressive intention tremor and gait ataxia, although other features are also
present in a subset of the patients including Parkinsonism, peripheral neuropathy, autonomic
dysfunction, executive function deficits, and psychiatric disorders.7-11 Biochemical studies
of FXTAS reveal intranuclear inclusions in the central and peripheral nervous systems,
white matter damage throughout the cerebrum and cerebellum,12-14 and disturbed zinc and
iron metabolism that leads to iron accumulation in the cells and mitochondrial
dysfunction.15-17
Disturbed iron homeostasis commonly affects motor functioning in various
neurodegenerative disorders18 because of the high iron concentration and physiology of the
extrapyramidal system.19-21 Given the evidence of deregulated iron metabolism16 and motor
deficits as the primary clinical symptoms,5,10 it is highly likely that FXTAS involves the
extrapyramidal system. Indeed, structural abnormalities in the extrapyramidal structures
including the cerebellar peduncles and pontine areas in premutation carriers with and
without FXTAS have been reported.22,23 However, the involvement of the thalamus and
basal ganglia in premutation carriers has not previously been systematically examined.
Structural damage in the subcortical gray matter may manifest as changes in volume, tissue
microstructure, or iron concentration, all of which can be quantified using different MRI
techniques. High-resolution T1-weighted imaging is commonly used for detecting
macroscopic changes in volume. Diffusion tensor imaging (DTI)24,25 has been applied
broadly for characterizing tissue microstructure, commonly in the white matter but also
recently in the subcortical gray matter26,27 where organized white matter tracts pass through
and produce anisotropic water diffusion.28-30 Diffusion weighted imaging (DWI) has been
traditionally used for detecting cytotoxic edema in strokes.31,32 However, a recent report26
extended its utility to quantify iron concentration in the subcortical gray matter, supported
by the strong correlation between DWI hypointense signals and high iron concentration in
the thalamus and putamen in healthy adults.
The current investigation aimed to characterize potential structural damage associated with
the fragile X premutation in subcortical gray matter. We utilized T1-weighted and DTI scans
and took a multimodal-imaging analysis approach to measure volume, structural integrity,
and iron deposition. Based on existing evidence, we predicted volume atrophy, structural
integrity impairment, and DWI-signal loss in the subcortical gray matter in patients with
FXTAS as well as in premutation carriers without FXTAS although to a lesser extent.
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We studied 61 adult males (age 47-81 years) recruited for an on-going study of fragile X
premutation carriers: 14 healthy controls, 11 premutation carriers without FXTAS, and 36
premutation carriers diagnosed with FXTAS (Table 1). Only the age between the two
premutation groups showed a significant difference (t(45) = 2.05, p = 0.046). The controls
and 26 of the premutation carriers were studied in a recent investigation of abnormal age-
related changes in structural connectivity in fragile X premutation.23 All participants signed
informed consent according to the study protocols approved by the Institutional Review
Boards at the University of California Davis Medical Center.
Premutation alleles were identified using FMR1 DNA testing (Table 1).33,34 FXTAS
severity was assessed using FXTAS stage.35 Of the 11 carriers without FXTAS, 7 were
given a stage of 0 (no signs of FXTAS) and 4 were given a stage of 1 (subtle or questionable
tremor/balance problems with no interference in daily living). Structured Clinical Interviews
for DSM-IV (SCID-I) did not find significantly higher rate of psychiatric problems in stage
1 carriers (2/4 with lifetime mood disorder) compared to stage 0 premutation carriers (2/7
with lifetime mood disorder and/or current anxiety disorder) (odds ratio = 2.5, two-tailed p =
0.47). Of the 36 carriers with FXTAS, 10 were at FXTAS stage 2 (minor tremor/balance
problems with minor interference in daily living); 11 at stage 3 (moderate tremor/balance
problems with significant interference in daily living); 12 at stage 4 (severe tremor/balance
problems requiring a cane or walker); and 3 at stage 5 (use of a wheelchair on a daily basis).
MRI acquisition protocol
Neuroimaging was performed on a Trio 3T MRI scanner with an 8-channel head coil
(Siemens Medical Solutions). All images were acquired between 2007-2009 before a major
scanner upgrade, which caused DTI scans acquired before and after the upgrade to be
incomparable. High-resolution T1-weighted MPRAGE scans were acquired in 208 sagittal
slices of 0.95-mm thickness (no gap) with a 243-mm FOV, a 256 × 256 matrix interpolated
to 512 × 512, a 2,500-ms TR, a 4.33-ms TE, and 7° flip angle. DTI scans with 30 gradient
directions were obtained using a single-shot diffusion-weighted EPI sequence in 72 axial
sections of 1.9-mm thickness (no gap) with a 243-mm FOV, a 128 × 128 matrix, a 11,900-
ms TR, and a 92 ms TE. The diffusion sensitizing gradients were applied at a b-value of 700
s/mm². Five additional images with minimum diffusion weighting were also obtained.
Image segmentation
We performed automatic segmentation on the T1-weighted scans using FMRIB’s Integrated
Registration and Segmentation Tool (FIRST)36 distributed with the FMRIB Software
Library (FSL; www.fmrib.ox.ac.uk/fsl/, University of Oxford). FIRST takes the Bayesian
approach to determine structural boundaries based on shape (manually pre-defined) and
image intensity. We selected the thalamus, caudate nucleus, putamen, and globus pallidus
for the analysis. The segmentations were checked and manually corrected for errors using
FSLView from FSL.37 Then masks were generated from the resulting segmentation, eroded
1 voxel for the putamen and pallidus, 2 voxels for the caudate, and 3 voxels for the thalamus
using the FSL function, fslmaths. The amount of erosion was determined after
superimposing the masks on coregistered mean diffusivity (MD) maps generated from DTI
(see below) to avoid contamination from the CSF (see Fig. 1).
Image registration
DTI images were first corrected for motion and eddy current using the eddy_correct function
from FSL. DTI Studio (cmrm.med.jhmi.edu/, Johns Hopkins Medical Institute) was then
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used for calculating tensor and generating mean b0 images, DWI images (i.e. the average of
all images with diffusion weighting), and fractional anisotropy (FA) and MD maps.
FreeSurfer (surfer.nmr.mgh.harvard.edu, Athinoula A. Martinos Center for Biomedical
Imaging) was utilized for co-registering MD maps with T1 (in FreeSurfer space) and then
transforming the MD maps to each subject’s native space. The co-registration was inspected
and manually adjusted to maximize the match of the lateral ventricles between the T1 and
MD maps. The resulting transforming matrices were then applied to the FA maps, and b0
and DWI images. Finally, the FSL tool, fslstats, was used to calculate the volume and
average values of FA, MD, and DWI for each mask.
Statistical analyses
For group comparisons, multiple linear regression was conducted using age and group as
independent variables and individual brain measurements (i.e. the volume, FA, MD, and
DWI of eight subcortical gray matter areas) as dependent variables. Total cranial volume
(TCV) calculated using Sienax from FSL38 was used as an additional covariate for volume.
Benjamini-Hochberg’s false discovery rate (FDR)39at 5% was used to correct for multiple
comparisons for each type of measurements.O’Brien’s test for homogeneity of variance40
(www.mathworks.com/matlabcentral/fileexchange/3510-homvar/content/OBrientest.m) was
conducted to test for differences in variance across diagnostic groups. Assumptions of the
regression models were checked and verified in the data. In addition, ordinal regression
using a proportional odds model was performedtopredict FXTAS stage from brain
measurements, using age as a covariate for FA, MD, and DWI, and both age and TCV for
volume. The FXTAS variable was recoded so that the model predicted the odds of being in
higher FXTAS stages. Assumptions of the proportional odds model were checked and were
met except where noted. For the O’Brien’s tests and ordinal regression, FDR was applied to
all tests that were performed and the threshold was set at 5%. We reported uncorrected p-
values and specifically indicated significant results according to the FDR procedure. The
statistical tests were carried out using Matlab scripts (The Mathworks Inc.) except for
ordinal regression, which was conducted using SPSS (IBM Corp.).
Results
Group comparisons
Figure 2 displays the group mean and SD of the subcortical structures. As some of the FA
and MD measurements showed high inter-subject variability in the premutation groups,
O’Brien’s test for homogeneity of variance40 was performed to detect potential differences
in variances. None of the FA and MD measurements showed significant differences in
variances at 5% FDR although the MD of left thalamus and left globus pallidus exhibited
differences in variances at raw p-values < 0.05 (F(2,58) = 3.6 and 4.5, p = 0.03 and 0.02,
respectively).
For the comparisons of group means, while none of the areas displayed significantly reduced
volume in the non-FXTAS group, 6 of the 8 subcortical areas showed significant atrophy in
the FXTAS group compared to the control group. These were bilateral thalamus and
putamen, left caudate, and right pallidus. In addition, the FXTAS group exhibited significant
DWI hypointensity in bilateral thalamus, caudate, and putamen, and right pallidus compared
to the controls. In the comparisons between FXTAS and non-FXTAS groups, the FXTAS
group showed volume atrophy in bilateral thalamus and putamen and DWI signal loss in
bilateral putamen, right thalamus, and left caudate (Table 2). In contrast, no differences in
FA or MD were detected between any of the groups.
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Correlation with FXTAS stage
We further tested the functional significance of the changes in the subcortical gray matter by
conducting ordinal regression analyses to predict FXTAS stage, combining the FXTAS and
non-FXTAS groups (n = 47). For the volume measurements, bilateral thalamus and putamen
and left caudate showed significant negative correlations with FXTAS stage after adjusting
for age and TCV. Additionally, the FA of bilateral caudate showed significant positive
correlation with FXTAS and DWI of left caudate and right putamen showed negative
correlation after adjusting for age (Table 3). To verify whether the tests met the proportional
odds assumption (i.e. the odds ratio for the association between the independent variable and
dichotomized FXTAS stage is the same regardless of what cut point is used for
dichotomizing FXTAS stage), we checked the results of likelihood ratio test. At α level
0.05, two measurements, right thalamic volume and left caudate DWI, did not pass the test.
To exclude the possibility that the relationships between the brain measurements and
FXTAS stage were mostly driven by the differences between FXTAS and non-FXTAS
patients, we further performed ordinal regression including only the FXTAS patients (n =
36) for these two measurements. While the correlation between right thalamic volume and
FXTAS stage remained significant (odds ratio = 1.14, 95% CI = 1.03-1.25, p = 0.008), left
caudate DWI no longer correlated with FXTAS stage (odds ratio = 1.02, 95% CI =
0.97-1.07, p = 0.46).
Discussion
We applied multimodal imaging analysis to characterize the extent and type of structural
damage in the subcortical gray matter in male premutation carriers with and without
FXTAS. In the FXTAS group, all 4 subcortical structures under-investigation (i.e. the
thalamus, caudate nucleus, putamen, and globus pallidus) exhibited volume atrophy
compared to the control group. Some structures showed potential iron-deposition,
manifested as DWI signal reduction. The FXTAS group also displayed significant volume
reduction and DWI signal loss in the thalamus and striatum compared to the non-FXTAS
premutation group. In comparison, no differences in FA or MD were detected between the
groups.
Group-mean comparisons revealed volume atrophy in all 4 structures for the FXTAS group
(Table 2). This is in contrast to our previous voxel-based morphological analysis, in which
only the thalamus, but not the basal ganglia, showed decreased T1-signal intensity in
FXTAS carriers.41 Improved image quality due to higher MRI static field strength (3T
versus 1.5T), and the utilization of an image-processing tool specifically designed for
registering and segmenting the subcortical gray matter, might have contributed to the greater
sensitivity in detecting the basal ganglia changes in the current investigation.
The involvement of the thalamus and basal ganglia in FXTAS is consistent with the
functions carried by these structures, which extend beyond simple motor control to
cognitive, motivational, and emotional processing during learning and execution of complex
behaviors.42 The basal ganglia and thalamus are the central components of the cortical-basal
ganglia-thalamic-cortical network.42,43 While all areas of the neocortex provide input to the
basal ganglia, which in turn projects massively to the thalamus, thalamic output mostly
targets the frontal cortex, with the temporal, parietal, and brain stem areas receiving minor
output. This asymmetric information flow suggests a general purpose role of the basal
ganglia and thalamus in performing information sorting, integration, and redirection for high
level processing in the frontal cortex.42-44 Structural damage in the thalamus and basal
ganglia can thus cause a profound effect on various types of brain processing and may
contribute to functional deficits in FXTAS that include not only motor, but also cognitive,
social, and emotional processing.7-9,45
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Given the high negative correlation between DWI signal intensity and iron concentration in
the thalamus and putamen,26 we examined DWI signal intensity and found significant
reduction in the thalamus and basal ganglia in the FXTAS group (Table 2). The DWI signal
reduction was especially robust in bilateral caudate, as the group differences remained
significant (t = -4.02 and -3.88, p = 0.0002 and 0.0003, respectively, for left and right) after
adding volume as an additional covariate to account for the effect of the same amount of
iron contained in shrinking tissues. The biochemical reports of mitochondrial dysfunction in
the fibroblasts and cortical neurons from premutation carriers with and without FXTAS15,16
corroborate well with our results. Dysregulated zinc and iron metabolisms disrupt
mitochondrial function. One of the downstream consequences is iron accumulation in the
cells, which is supported by the improved mitochondrial function in the fibroblasts treated
with both Zn supplement and an iron chelator.16
With regards to the association with FXTAS stage, we found that more advanced stages of
FXTAS were associated with volume atrophy in the thalamus and striatum and DWI signal
reduction in the putamen, indicating gradual tissue loss and iron accumulation as motor
function becomes more impaired (Table 3). In addition, bilateral caudate nucleus showed
significant positive correlation between FA and FXTAS stage, an apparent counter-intuitive
finding. We performed further correlational analysis and found negative correlations
between caudate FA and volume (r = -0.55, p < 0.001), MD (r = -0.49, p < 0.001), and DWI
(r = -0.29, p = 0.051). The head of caudate, contributing the most to the caudate
measurements, contains the frontal-striatal pathway. The patterns of change may indicate
preferential loss of striatal cell bodies and relatively spared frontal-striatal pathway in
FXTAS. Longitudinal studies tracking patients from early to advanced stage of FXTAS are
necessary to confirm this interpretation.
As we were utilizing MRI scans acquired from 2007-2009, the most significant limitation of
the current study was not being able to use a MRI sequence designed specifically for
quantifying iron deposition. Consequently, the results regarding the iron accumulation need
to be confirmed using a standard imaging technique, for instance the susceptibility-weighted
imaging, R2*, and field dependent relaxation increase (FDRI).19,46-49 In addition,
intermodal image registration is challenging especially in the case of EPI sequences with
substantial susceptibility-related distortion. Although considerable effort and care was taken
to manually adjust the registration, minor errors may still exist. Other limitations include the
inability of DTI in pinpointing the exact type of damage that has occurred in tissues
containing a mixture of cell bodies and axons. As we analyzed the thalamus as a whole, our
findings may not be applicable to all thalamic nuclei, each of which connects with distinct
cortical and subcortical structures to support diverse brain functions. We are currently
conducting DTI tractography-based segmentation of the thalamus50 to further identify the
nuclei that are especially vulnerable to FXTAS.
In conclusion, this study revealed critical involvement of the thalamus and basal ganglia in
FXTAS. All 4 structures exhibited changes in a multitude of measurements in the FXTAS
group. Importantly, thalamic and striatal measurements demonstrated functional significance
by showing significant correlation with FXTAS stage. These results indicate the need for
further studies to verify the benefit of tracking structural changes in the subcortical gray
matter for making prognosis, monitoring disease progression, and determining effectiveness
of therapeutic treatment of FXTAS.
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Segmentation of subcortical gray matter. A-C: T1-weighted images; D-F: MD maps. Green,
thalamus; light green, caudate nucleus; light blue, putamen; blue, globus pallidus.
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Group mean and SD of the subcortical gray matter structures. *, significant group mean
difference at 5% FDR, p ≤ 0.015 for volume and 0.021 for DWI.
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Table 1
Characteristics of 61 research participants: mean (SD) [range]
Characteristics HC (n= 14) NFPC (n= 11) FXTAS (n= 36)
Age (years) 61.6 (7.7) [52-81] 60.1 (10.6) [47–76] 65.8 (7.1) [50–79]
FMR1 CGG repeat size 28.2 (6.0) [19–42] 80.5 (17.2) [59–113] 96.5 (20.9) [62–154]
FMR1 mRNA level 1.5 (0.2) [1.0–1.8] 2.5 (0.8) [1.4–4.1] 3.1 (0.8) [1.6–5.6]
Abbreviations: NFPC, non-FXTAS premutation carriers; HC, healthy controls.
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